Arenavirus Inhibitor

Arenavirus Inhibitors (22):

Cat. No.	Product Name	Effect	Purity

HY-14805

Tecovirimat	Inhibitor	99.88%
Tecovirimat (ST-246) is an orally bioavailable and selective compound against orthopoxviruses including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus.

HY-13560

AVN-944	Inhibitor	99.89%
AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) and acute myeloid leukemia (AML) research.

HY-13963

ZCL278	Inhibitor	98.49%
ZCL278 is a selective Cdc42 inhibitor with K_ds of 6.4 μM in fluorescence titration and 11.4 μM in surface plasmon resonance (SPR) measurement. ZCL278 is able to disrupt the Cdc42-ITSN interaction as well as GTP/GDP binding. ZCL278 has inhibitory effects on various enveloped viruses, but is ineffective against non-enveloped viruses. ZCL278 can be used for the studies of arsenic neurotoxicity and HER2-positive gastric cancer (GC).

HY-112762

LHF-535	Inhibitor	99.14%
LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC₅₀s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.

HY-P992155

Arevirumab	Inhibitor
Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever.

HY-W1135843

ARN-75039	Inhibitor
ARN-75039 is an orally active arenavirus inhibitor. ARN-75039 binds to sites on the GP2 subunit of the mammarenavirus glycoprotein complex, stabilizes prefusion conformation, and blocks viral entry and endosomal membrane fusion to inhibit viral replication and spread. ARN-75039 can be used for the research of lassa fever, arenaviral hemorrhagic fever, and lethal Junín virus infection.

HY-101441

ST-193	Inhibitor	99.93%
ST-193 is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC₅₀ values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.

HY-P0323A

GP(33-41) TFA	Inhibitor	99.62%
GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2D^b molecules at the RMA-S (Db Kb) cell surface with a SC₅₀ of 344 nM.

HY-114698

Retro-2 cycl	Inhibitor	99.17%
Retro-2 cycl (RN 1-001) is a retrograde transport inhibitor with antiviral activity. Retro-2 cycl (RN 1-001) inhibits JCPyV and HPV16 pseudoviruses, with an IC₅₀ of 54 μM and 160 μM respectively.

HY-172918

VV261	Inhibitor	99.92%
VV261 is an orally active prodrug of 4'-fluorouridine. VV261 inhibits viral RNA-dependent RNA polymerase. VV261 exhibits antiviral activity against CCHFV, SFTSV and LCMV. VV261 can be used in research related to viral infections.

HY-14805A

Tecovirimat monohydrate	Inhibitor
Tecovirimat (ST-246) monohydrate is the monohydrate form of Tecovirimat (HY-14805). Tecovirimat monohydrate is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat monohydrate is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat monohydrate targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat monohydrate exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat monohydrate could be used in the study for orthopoxvirus-induced diseases.

HY-N10113

Verrucarin J	Inhibitor	99.9%
Verrucarin J (Muconomycin B) is a metabolite of the Myrothecium fungus family. Verrucarin J generates reactive oxygen species (ROS) and induces apoptosis of cancer cell lines, such as A549, HCT 116 and SW-620 cells. Verrucarin J shows activities against Candida albicans and Mucor miehei. Verrucarin J inhibits arenavirus Junin (JUNV) yield with an IC₅₀ of 1.2 ng/mL.

HY-P990166

Anti-Mouse PSGL-1/CD162 Antibody (4RA10)	Inhibitor
Anti-Mouse PSGL-1/CD162 Antibody (4RA10) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse PSGL-1/CD162. Anti-Mouse PSGL-1/CD162 Antibody (4RA10) blocks PSGL signaling and inhibits leukocyte rolling. Anti-Mouse PSGL-1/CD162 Antibody (4RA10) can be used for the researches of inflammation, immunology and infection, such as pneumonia and lymphocytic choriomeningitis virus infection.

HY-112762A

(E)-LHF-535	Inhibitor	99.21%
(E)-LHF-535 is the E-isomer of LHF-535. LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC₅₀s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.

HY-124871

LASV-IN-1	Inhibitor	99.85%
LASV-IN-1 is a Lassa fever virus (LASV) inhibitor. LASV-IN-1 binds with LASV glycoprotein (GP) and promotes virus membrane fusion and infection. LASV-IN-1 can be used for LASV infection research.

HY-101441A

ST-193 hydrochloride	Inhibitor	98.76%
ST-193 hydrochloride is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC₅₀ values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.

HY-14805S

Tecovirimat-d₄	Inhibitor	98.95%
Tecovirimat-d₄ (ST-246-d₄) is a deuterium-labelled Tecovirimat (HY-14805). Tecovirimat is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat could be used in the study for orthopoxvirus-induced diseases.

HY-P990810

Anti-LCMV Nucleoprotein Antibody (VL-4)	Inhibitor	99%
Anti-LCMV Nucleoprotein Antibody (VL-4) is rat-derived IgG2a κ type antibody inhibitor, targeting to LCMV nucleoprotein. Anti-LCMV Nucleoprotein Antibody (VL-4) reacts with lymphocytic choriomeningitis virus (LCMV) nucleoprotein. Anti-LCMV Nucleoprotein Antibody (VL-4) stain LCMV-infected cell internally with no surface staining. Anti-LCMV Nucleoprotein Antibody (VL-4) can be used for the detections of immunohistochemistry and flow cytometry in LCMV infection.

HY-170799

HNC-1664	Inhibitor
HNC-1664 is the orally active inhibitor for RNA-dependent RNA polymerase (RdRP). HNC-1664 exhibits broad-spectrum antiviral activity against coronavirus (SARS-CoV-2 wildtype and its mutants XBB.1.18, HK.3.1, BF.7.14, BA.1HCoV-229E, HCoV-OC43) and arenavirus. HNC-1664 exhibits anti-infectious activity in SARS-CoV-2 Delta infected mouse models.

HY-183708

Antiviral agent 85	Inhibitor
Antiviral agent 85 is a broad-spectrum arenavirus entry inhibitor with an EC₉₀ of 0.13 µM against Junín virus (JUNV). Antiviral agent 85 blocks the entry of various arenaviruses through both hTfR1-dependent and hTfR1-independent pathways, acting on the early and early post-entry stages of infection. Antiviral agent 85 exhibits antiviral activity against a variety of arenaviruses, is well tolerated in hTfR1-expressing JUNV-infected mouse models, but fails to provide protective effects. Antiviral agent 85 can be used in studies related to arenavirus hemorrhagic fevers.

Name
Email *

	Sorry, but the email address you supplied was invalid.